Related Experiment Video
Updated: Jun 27, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Emerging drugs for colorectal cancer
David R Fogelman1, Scott Kopetz, Cathy Eng
1MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA. dfogelman@mdanderson.org
Background:
The past 5 years have shown major advances in the treatment of colorectal cancer. Our understanding of existing drugs, such as oxaliplatin and irinotecan, has become more refined. The incorporation of newer drugs such as bevacizumab and cetuximab has expanded treatment options as well.
Objective:
Our goals are to review the evidence for currently approved drugs, with particular attention to the most recent studies highlighting the ideal conditions for each. In addition, we discuss current areas of investigation - particularly, specific pathway inhibitors - that are most relevant for colorectal cancer.
Methods:
We have used existing literature as well as abstracts and oral presentations from ASCO and AACR meetings.
Results/Conclusion:
We report current thinking on the use of existing drugs, and present the most promising novel pathway inhibitors that are now being developed for colorectal cancer.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs that Stabilize Microtubules
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Constipation-Predominant IBS
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

